The Journal of Urology
Volume 183, Issue 2 , Pages 743-751, February 2010

The miR-17-92 Cluster is Over Expressed in and Has an Oncogenic Effect on Renal Cell Carcinoma

  • Tsz-fung F. Chow

      Affiliations

    • Department of Laboratory Medicine and Keenan Research Centre, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada
  • ,
  • Marina Mankaruos

      Affiliations

    • Department of Laboratory Medicine and Keenan Research Centre, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada
  • ,
  • Andreas Scorilas

      Affiliations

    • Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Athens, Panepistimiopolis, Athens, Greece
  • ,
  • Youssef Youssef

      Affiliations

    • Department of Laboratory Medicine and Keenan Research Centre, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada
  • ,
  • Andrew Girgis

      Affiliations

    • Department of Laboratory Medicine and Keenan Research Centre, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada
  • ,
  • Sarah Mossad

      Affiliations

    • Department of Laboratory Medicine and Keenan Research Centre, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada
  • ,
  • Shereen Metias

      Affiliations

    • Department of Laboratory Medicine and Keenan Research Centre, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada
  • ,
  • Yostina Rofael

      Affiliations

    • Department of Laboratory Medicine and Keenan Research Centre, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada
  • ,
  • R. John Honey

      Affiliations

    • Division of Urology, Department of Surgery, St. Michael's Hospital, Toronto, Ontario, Canada
    • Financial interest and/or other relationship with Cook and Pleuromed.
  • ,
  • Robert Stewart

      Affiliations

    • Division of Urology, Department of Surgery, St. Michael's Hospital, Toronto, Ontario, Canada
  • ,
  • Kenneth T. Pace

      Affiliations

    • Division of Urology, Department of Surgery, St. Michael's Hospital, Toronto, Ontario, Canada
    • Financial interest and/or other relationship with Sanofi-Synthelabo.
  • ,
  • George M. Yousef

      Affiliations

    • Department of Laboratory Medicine and Keenan Research Centre, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada
    • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
    • Corresponding Author InformationCorrespondence and requests for reprints: Department of Laboratory Medicine, St. Michael's Hospital, 30 Bond St., Toronto, Ontario, M5B 1W8, Canada (telephone: 416-864-6060, extension 6129; FAX: 416-864-5648)

Received 29 April 2009 published online 17 December 2009.

Purpose

miRNAs are small, nonprotein coding RNAs that are differentially expressed in many malignancies. We previously identified 80 miRNAs that are dysregulated in clear cell renal cell carcinoma. In this study we validated over expression of the miR-17-92 cluster in clear cell renal cell carcinoma and tested the effect of 2 members of this cluster (miR-17-5p and miR-20a) on tumor proliferation. We also elucidated the role of miRNA in clear cell renal cell carcinoma pathogenesis with bioinformatics.

Materials and Methods

miRNA expression was validated by quantitative reverse transcriptase-polymerase chain reaction. The cell proliferation effect of miR-17-5p and miR-20a was tested in a renal adenocarcinoma cell line model. Multiple in silico analyses were done of dysregulated miRNAs.

Results

We validated miR-71-92 cluster over expression in clear cell renal cell carcinoma by quantitative reverse transcriptase-polymerase chain reaction. Transfection of miR-20a inhibitor significantly decreased cell proliferation in a dose dependent manner. Transfection of miR-17-5p, which is not endogenously expressed in the ACHN cell line, led to increased cell proliferation compared to control values. This effect was suppressed by miR-17-5p inhibitor. Bioinformatics analysis identified 10 clusters of miRNAs dysregulated in clear cell renal cell carcinoma that followed the same expression patterns. We also identified matching patterns between reported chromosomal aberration in clear cell renal cell carcinoma and miRNA dysregulation for 37.5% of the miRNAs. Target prediction analysis was done using multiple algorithms. Many key molecules in clear cell renal cell carcinoma pathogenesis, including HIFs, mTOR, VEGF and VHL, were potential targets for dysregulated miRNAs.

Conclusions

A significant number of dysregulated proteins in clear cell renal cell carcinoma are potential miRNA targets. Also, many clear cell renal cell carcinoma dysregulated miRNAs are phylogenetically conserved.

Key Words: kidney, carcinoma, renal cell, microRNAs, computational biology, oncogenes

Abbreviations and Acronyms: ccRCC, clear cell RCC, Ct, cycle threshold, HIF, hypoxia-induced factor, PCR, polymerase chain reaction, PI3K, phosphatidylinositol 3-kinase, PTEN, phosphatase and tensin homologue deleted on chromosome 10, qRT-PCR, quantitative reverse transcriptase-PCR, RCC, renal cell carcinoma, VEGF, vascular endothelial growth factor, VHL, von Hippel-Lindau

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Study received approval from the research ethics board, St. Michael's Hospital, Toronto, Canada.

 Supported by Canadian Institute of Health Research Grant 86490.

 Supplementary material for this article can be obtained at http://www.stmichaelshospital.com/pdf/labs/suppl-fig-1.pdf, http://www.stmichaelshospital.com/pdf/labs/suppl-fig-2.pdf, http://www.stmichaelshospital.com/pdf/labs/suppl-tbl-1.pdf, http://www.stmichaelshospital.com/pdf/labs/suppl-tbl-2.pdf and http://www.stmichaelshospital.com/pdf/labs/suppl-tbl-3.pdf.

PII: S0022-5347(09)02627-5

doi:10.1016/j.juro.2009.09.086

The Journal of Urology
Volume 183, Issue 2 , Pages 743-751, February 2010